Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults
Nomura Core Equity Fund Q2 2026 Portfolio Review
12:35pm, Wednesday, 22'nd Jul 2026
Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial int
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
12:25pm, Wednesday, 22'nd Jul 2026
The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
10:00am, Wednesday, 22'nd Jul 2026
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
06:45am, Wednesday, 22'nd Jul 2026
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
These major drug stocks rally after Trump's zero tariff announcement
06:31am, Wednesday, 22'nd Jul 2026
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
01:32pm, Tuesday, 21'st Jul 2026
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Novo Sues Rival Lilly Over Weight-Loss Ads
10:21am, Tuesday, 21'st Jul 2026
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'
Cramer's Mad Dash: Eli Lilly
10:12am, Tuesday, 21'st Jul 2026
CNBC's Jim Cramer delivers his daily Mad Dash.
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
08:33am, Tuesday, 21'st Jul 2026
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss dr
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
07:57am, Tuesday, 21'st Jul 2026
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
07:38am, Tuesday, 21'st Jul 2026
Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
06:46pm, Monday, 20'th Jul 2026
In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
02:10pm, Monday, 20'th Jul 2026
Lilly stock has soared in the double-digits over the past couple of months. A potential stock split could bring the stock price down to more accessible levels.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
10:44am, Monday, 20'th Jul 2026
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
